|
1
|
Fitzmaurice C, Allen C, Barber RM,
Barregard L, Bhutta ZA, Brenner H, et al: Global, regional, and
national cancer incidence, mortality, years of life lost, years
lived with disability, and disability-adjusted life-years for 32
cancer groups, 1990 to 2015: A systematic analysis for the global
burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kolahdoozan S, Sadjadi A, Radmard AR and
Khademi H: Five common cancers in Iran. Arch Iran Med. 13:143–146.
2010.PubMed/NCBI
|
|
5
|
Mousavi SM, Montazeri A, Mohagheghi MA,
Jarrahi AM, Harirchi I, Najafi M and Ebrahimi M: Breast cancer in
Iran: An epidemiological review. Breast J. 13:383–391. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karimi A, Shandiz FH, Sharifzadeh GR,
Zoubin F, Fatemeh T and Rahmani S: Breast cancer in Iran. Life Sci
J. 10:2013.PubMed/NCBI
|
|
7
|
Kumar G: Symptom Clusters and Quality of
Life Trajectories in Breast Cancer Patients Before and After
Chemotherapy. University of Nebraska Medical Center. 2018.
|
|
8
|
Motaghed M: Cytotoxic, cytostatic and
anti-estrogenic effect of Thymoquinone on estrogen
receptor-positive breast cancer MCF7 cell line. American Journal of
Life Sciences. 3:7–14. 2015. View Article : Google Scholar
|
|
9
|
Hoskins JM, Carey LA and McLeod HL: CYP2D6
and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer.
9:576–586. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taylor R and Taguchi K: Tamoxifen for
breast cancer chemoprevention: Low uptake by high-risk women after
evaluation of a breast lump. Ann Fam Med. 3:242–247. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar KS and Kumar MM: Antiestrogen
therapy for Breast Cancer: An overview. Cancer Ther. 6:2008.
|
|
12
|
Kiyotani K, Mushiroda T, Sasa M, Bando Y,
Sumitomo I, Hosono N, Kubo M, Nakamura Y and Zembutsu H: Impact of
CYP2D6*10 on recurrence-free survival in breast cancer patients
receiving adjuvant tamoxifen therapy. Cancer Sci. 99:995–999. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morrow PK, Serna R, Broglio K, Pusztai L,
Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G,
et al: Effect of CYP2D6 polymorphisms on breast cancer recurrence.
Cancer. 118:1221–1227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Group EBCTC: Tamoxifen for early breast
cancer: An overview of the randomised trials. Early Breast Cancer
Trialists' Collaborative Group. Lancet. 351:1451–1467. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bertilsson L, Dahl ML, Dalén P and
Al-Shurbaji A: Molecular genetics of CYP2D6: Clinical relevance
with focus on psychotropic drugs. Br J Clin Pharmacol. 53:111–122.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Schaik RH: Cancer treatment and
pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs.
23:513–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai DP, Geng PW, Wang SH, Cai J, Hu LM,
Nie JJ, Hu JH, Hu GX and Cai JP: In vitro functional assessment of
22 newly identified CYP2D6 allelic variants in the Chinese
population. Basic Clin Pharmacol Toxicol. 117:39–43. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chin FW, Chan SC, Rahman Abdul S, Noor
Akmal S and Rosli R: CYP2D6 genetic polymorphisms and phenotypes in
different ethnicities of Malaysian breast cancer patients. Breast
J. 22:54–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yagihashi T, Mizuno M, Chino B, Sato Y,
Sakuma K, Takebayashi T, Takao T and Kosaki K: Effects of the
CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on
risperidone metabolism in patients with schizophrenia. Hum
Psychopharmacol. 24:301–308. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
McLellan RA, Oscarson M, Seidegård J,
Evans DA and Ingelman-Sundberg M: Frequent occurrence of CYP2D6
gene duplication in Saudi Arabians. Pharmacogenetics. 7:187–191.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu
SN and Wang DM: Genetic polymorphism, linkage disequilibrium,
haplotype structure and novel allele analysis of CYP2C19 and CYP2D6
in Han Chinese. Pharmacogenomics J. 9:380–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishida Y, Fukuda T, Yamamoto I and Azuma
J: CYP2D6 genotypes in a Japanese population: Low frequencies of
CYP2D6 gene duplication but high frequency of CYP2D6*10.
Pharmacogenetics. 10:567–570. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rungwanonchai P, Ayudhya DPN, Areepium N,
Voravud N and Satthaporn S: Prevalence of CYP2D6* 10 Genotype in
Thai Breast Cancer Patients. Wētchasān phǣt Thahān Bok. 65:113–118.
2012.
|
|
24
|
Roepman P, Horlings HM, Krijgsman O, Kok
M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver
MJ, et al: Microarray-based determination of estrogen receptor,
progesterone receptor, and HER2 receptor status in breast cancer.
Clin Cancer Res. 15:7003–7011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bagheri A, Kamalidehghan B, Haghshenas M,
Azadfar P, Akbari L, Sangtarash MH, Vejdandoust F, Ahmadipour F,
Meng GY and Houshmand M: Prevalence of the CYP2D6*10 (C100T), *4
(G1846A), and *14 (G1758A) alleles among Iranians of different
ethnicities. Drug Des Devel Ther. 9:2627–2634. 2015.PubMed/NCBI
|
|
26
|
Kouhi H, Hamzeiy H, Barar J, Asadi M and
Omidi Y: Frequency of five important CYP2D6 alleles within an
Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers.
13:665–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou LP, Luan H, Dong XH, Jin GJ, Man DL
and Shang H: Genetic variants of CYP2D6 gene and cancer risk: A
HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev.
13:3165–3172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gutman G, Morad T, Peleg B, Peretz C,
Bar-Am A, Safra T and Grisaru D: CYP1A1 and CYP2D6 gene
polymorphisms in Israeli Jewish women with cervical cancer. Int J
Gynecol Cancer. 19:1300–1302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teh LK and Bertilsson L: Pharmacogenomics
of CYP2D6: Molecular genetics, interethnic differences and clinical
importance. Drug Metab Pharmacokinet. 27:55–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oscarson M: Pharmacogenetics of drug
metabolising enzymes: Importance for personalised medicine. Clin
Chem Lab Med. 41:573–580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ramamoorthy Y, Tyndale RF and Sellers EM:
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in
catalytic activity for multiple substrates. Pharmacogenetics.
11:477–487. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T,
Li J, Wang T, Fan Z, Fan T, et al: Association between CYP2D6 *10
genotype and survival of breast cancer patients receiving tamoxifen
treatment. Ann Oncol. 19:1423–1429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
LLerena A, Naranjo MEG, Rodrigues-Soares
F, Penas-LLedó EM, Fariñas H and Tarazona-Santos E: Interethnic
variability of CYP2D6 alleles and of predicted and measured
metabolic phenotypes across world populations. Expert Opin Drug
Metab Toxicol. 10:1569–1583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG
and Kim JW: Sequence-based CYP2D6 genotyping in the Korean
population. Ther Drug Monit. 28:382–387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nazir N, Waheed A, Farhat K, Ismail M and
Mansoor Q: Frequency of CYP2D6*10 genotypes in Pakistani breast
cancer patients taking adjuvant tamoxifen. J Pak Med Assoc.
66:1554–1558. 2016.PubMed/NCBI
|
|
36
|
Naveen AT, Adithan C, Soya SS, Gerard N
and Krishnamoorthy R: CYP2D6 genetic polymorphism in South Indian
populations. Biol Pharm Bull. 29:1655–1658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yazdi MF, Rafieian S, Gholi-Nataj M,
Sheikhha MH, Nazari T and Neamatzadeh H: CYP2D6 Genotype and risk
of recurrence in tamoxifen treated breast cancer patients. Asian
Pac J Cancer Prev. 16:6783–6787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Erden G, Acar FS, Inal EE, Soydas AO,
Ozoran K, Bodur H and Yildirimkaya MM: Frequency of mutated allele
CYP2D6*4 in the Turkish ankylosing spondylitis patients and healthy
controls. Rheumatol Int. 29:1431–1434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Menoyo A, del Rio E and Baiget M:
Characterization of variant alleles of cytochrome CYP2D6 in a
Spanish population. Cell Biochem Funct. 24:381–385. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Ameida Melo M, De Vasconcelos-Valença
RJ, Neto FM, Borges RS, Costa-Silva DR, Da Conceição
Barros-Oliveira M, Borges US, Alencar AP, Silva VC and Da Silva BB:
CYP2D6 gene polymorphisms in Brazilian patients with breast cancer
treated with adjuvant tamoxifen and its association with disease
recurrence. Biomed Rep. 5:574–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Borges S, Desta Z, Li L, Skaar TC, Ward
BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM and Wu L:
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: Implication for optimization of breast cancer
treatment. Clin Pharmacol Ther. 80:61–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Teh LK, Ismail R, Yusoff R, Hussein A, Isa
MN and Rahman AR: Heterogeneity of the CYP2D6 gene among Malays in
Malaysia. J Clin Pharm Ther. 26:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Topić E, Stefanović M, Nikolić V, Zoricić
I, Ivanisević AM and Žuntar I: Detection of CYP2D6*3 and 2D6*4
allelic variants by PCR-restriction fragment length polymorphism.
Clin Chem Lab Med. 36:655–658. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Varela N, Quiñones LA, Stojanova J, Garay
J, Cáceres D, Cespedes S, Sasso J and Miranda C: Characterization
of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo
population through polymorphism analyses. Pharmacol Res.
101:124–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hashemi-Soteh SM, Sarzare F, Merat F,
Salehifar E and Shiran MR: Frequencies of three CYP2D6
nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian
population (Mazandaran). Genet Test Mol Biomarkers. 15:821–825.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aydin M, Hatirnaz O, Erensoy N and Ozbek
U: CYP2D6 and CYP1A1 mutations in the Turkish population. Cell
Biochem Funct. 23:133–135. 2005. View Article : Google Scholar : PubMed/NCBI
|
